ABBVAbbVieRunning, no new patients
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Chronic Lymphocytic Leukemia · Acute Myeloid Leukemia · Multiple Myeloma · Non-Hodgkin's Lymphoma · Acute Lymphoblastic Leukemia · Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 165 (final count)
- Started
- Sep 6, 2019
- Main results expected
- Aug 2027
- Fully finished
- Aug 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events
Measured over: From first dose of study drug until 30 days following last dose of study drug (up to approximately 5 years).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03844048 · record last updated 2026-05-13 · checked 2026-11-09 15:47 UTC